Watson Pharmaceuticals: Announcement on the approval of Liuwei Anshen capsules as the country\'s first grade 2 protected variety of traditional Chinese medicine
Watson Pharmaceuticals: Announcement on changes in the company\'s drug production license
Watson Pharmaceuticals: Notice on receipt of approval letter for drug re-registration
Watson Pharmaceuticals: Announcement on the approval of licorice and plum tablets for registration in Singapore
Chongqing Pharscin Pharmaceutical: Notice Regarding the Online Mid-Year Performance Briefing for 2024
Chongqing Pharscin Pharmaceutical: Announcement on the Action Plan for Double Improvement of Quality and Profit
Chongqing Pharscin Pharmaceutical: Financial Report for the first half of 2024.
Chongqing Pharscin Pharmaceutical: Summary table of non-operating funds utilization and other related funds flow for the first half of the year.
Chongqing Pharscin Pharmaceutical: Announcement regarding the receipt of pharmaceutical re-registration approval notice.
Chongqing Pharscin Pharmaceutical: Announcement Regarding Completing Domestic Production Pharmaceutical Filing for the Product.
Chongqing Pharscin Pharmaceutical: Announcement Regarding Completion of Business Registration Changes.
Chongqing Pharscin Pharmaceutical: Announcement regarding the receipt of approval notice for re-registration of active pharmaceutical ingredient.
Chongqing Pharscin Pharmaceutical: Announcement Regarding Changes to the Company's Pharmaceutical Production License
Chongqing Pharscin Pharmaceutical: Announcement Regarding Completing Domestic Production Pharmaceutical Filing for the Product.
Chongqing Pharscin Pharmaceutical: Notice on the approval of Bawei Qalong granules as the country's first grade 2 protected variety of traditional Chinese medicine
Chongqing Pharscin Pharmaceutical: Legal Opinion of Shanghai Zechang Law Firm on the 2023 Annual General Meeting of Shareholders of Chongqing Huasen Pharmaceutical Co., Ltd.
Chongqing Pharscin Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Chongqing Pharscin Pharmaceutical: Announcement on changes in the company's pharmaceutical production license
Chongqing Pharscin Pharmaceutical: Announcement on Cancelling Some Proposals of the 2023 Annual General Meeting of Shareholders and the Supplementary Notice of the 2023 Annual General Meeting of Shareholders
Chongqing Pharscin Pharmaceutical: Notice on holding an online briefing session on the results for the first quarter of 2023 and 2024
No Data
No Data